PRN: New Review Provides an Overview of Triptans in the Treatment of Acute Migraine

19/set/2017 13:15:34 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 6 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

New Review Provides an Overview of Triptans in the Treatment of Acute Migraine

 
[19-September-2017]
 

LONDON, September 19, 2017 /PRNewswire/ --

Pietro Cortelli, Gianni Allais, Chiara Benedetto, European Neurological Review , 2017;12(2):Epub ahead of print

     (Logo: http://mma.prnewswire.com/media/515766/Touch_Medical_Logo.jpg )

Recently published online in European Neurological Review the peer-reviewed journal from touchNEUROLOGY, Cortelli et al, discuss how the advent of triptans for effective relief of migraine represented a therapeutic breakthrough. Triptans are serotonin (5-hydroxytryptamine, or 5-HT) agonists with high affinity for 5-HT1B and 5-HT1D receptors. There are, at present, seven commonly used triptans: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan. Some controversy still surrounds the mode of action of this class. When first studied, it was thought that triptans provided relief from migraine through cranial vasoconstriction, probably via action at postsynaptic 5-HT1B receptors on the smooth-muscle cells of blood vessels. More recently, however, triptans have also been demonstrated to block release of vasoactive peptides from the perivascular trigeminal neurons owing to their action at ! presynaptic 5-HT1D receptors on the nerve terminal. Triptans may also facilitate descending pain inhibitory systems. However, it is not certain whether or not the activation of vascular 5-HT1B receptors is essential for relieving migraine. Many drug characteristics need to be taken into account when selecting the best triptan for an individual patient. Clinical characteristics of the migraine attack and the patient's lifestyle and medical history are also important. Despite their biochemical similarity, triptans have distinct pharmacokinetic and pharmacodynamic profiles. Frovatriptan and naratriptan, for example, have a longer half-life and therefore a delayed onset of action and prolonged duration compared with the other triptans, which are fast acting, with a rapid dose-dependent efficacy and higher risk of adverse events and migraine recurrence. Migraine recurrence is affected by the pharmacological and pharmacokinetic properties of the triptan but ! is unrelated to initial clinical efficacy. Triptans with a lon! ger half -life and largest 5-HT1B receptor affinity have the lowest rates of headache recurrence.

The full peer-reviewed, open-access article is available here:

http://www.touchneurology.com/articles/overview-triptans-treatment-acute-migraine

Disclosure: Pietro Cortelli has received honoraria for speaking engagements or consulting activities with Allergan Italia, UCB Pharma SpA, Chiesi Farmaceutici, AbbVie SrL, Eli Lilly and Company, and Zambon. Gianni Allais and Chiara Benedetto have no conflicts to disclose in relation to this article.

touchNEUROLOGY (a division of Touch Medical Media) publishes European Neurological Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of neurology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.

www.touchNEUROLOGY.com

"Touch Medical Media is a trading name of Touch Digital Media Limited, a private limited company registered in England and Wales at The White House Mill Road, Goring, Reading, England, RG8 9DD with registered number 08197142".

For inquires please contact:
Christina Mackins-Crabtree, PhD, CMPP - Managing Editor
Christina.mackins@touchmedicalmedia.com

"Leading the Debate on the Advances in Healthcare"

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl